GenSight Biologics Beheer

Beheer criteriumcontroles 2/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Laurence Rodriguez

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	less than a year
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	3yrs
Gemiddelde ambtstermijn bestuur	10.1yrs

Recente managementupdates

Recent updates

Is There An Opportunity With GenSight Biologics S.A.'s (EPA:SIGHT) 30% Undervaluation?

Dec 22

GenSight Biologics S.A. (EPA:SIGHT) Shares Could Be 27% Below Their Intrinsic Value Estimate

Jun 14

GenSight Biologics S.A. (EPA:SIGHT): Is Breakeven Near?

May 10

Analysts Expect Breakeven For GenSight Biologics S.A. (EPA:SIGHT) Before Long

Feb 02

A Quick Analysis On GenSight Biologics' (EPA:SIGHT) CEO Salary

Dec 09

CEO

Laurence Rodriguez (56 yo)

less than a year

Tenure

Mrs. Laurence Rodriguez is Chief Executive Officer of GenSight Biologics S.A. from December 21, 2023 and has been its Director since January 12, 2024. Ms. Rodriguez has many years of experience in the life...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Laurence Rodriguez	CEO & Director	less than a year	geen gegevens	geen gegevens
Jose-Alain Sahel	Scientific Founder	no data	geen gegevens	geen gegevens
Botond Roska	Scientific Founder & Chairman of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Luk Vandenberghe	Scientific Founder & Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Serge Picaud	Scientific Founder & Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Constance Cepko	Scientific Founder & Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Jan Umiastowski	Chief Financial Officer	less than a year	geen gegevens	geen gegevens
Scott Jeffers	Chief Technical Officer	2.6yrs	geen gegevens	geen gegevens
Barrett Katz	Consultant	7.1yrs	geen gegevens	geen gegevens
Magali Taiël	Chief Medical Officer	5.1yrs	geen gegevens	geen gegevens
Marion Ghibaudo	Chief Technical Officer of Medical Device	3.4yrs	geen gegevens	geen gegevens

3.0yrs

Gemiddelde duur

Ervaren management: Het managementteam van SIGHT wordt beschouwd als ervaren (gemiddelde ambtstermijn 3 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Laurence Rodriguez	CEO & Director	less than a year	geen gegevens	geen gegevens
Jose-Alain Sahel	Scientific Founder	12.6yrs	geen gegevens	geen gegevens
Botond Roska	Scientific Founder & Chairman of Scientific Advisory Board	12.6yrs	geen gegevens	geen gegevens
Luk Vandenberghe	Scientific Founder & Member of Scientific Advisory Board	12.6yrs	geen gegevens	geen gegevens
Serge Picaud	Scientific Founder & Member of Scientific Advisory Board	12.6yrs	geen gegevens	geen gegevens
Constance Cepko	Scientific Founder & Member of Scientific Advisory Board	12.6yrs	geen gegevens	geen gegevens
Cédric Moreau	Representative Director	5.4yrs	geen gegevens	geen gegevens
Ernst Bamberg	Member of Scientific Advisory Board	12.6yrs	geen gegevens	geen gegevens
Maritza McIntyre	Independent Director	5.4yrs	€33.75k	geen gegevens
Simone Seiter	Independent Director	7.6yrs	€33.75k	geen gegevens
Elsy Boglioli	Independent Director	4.2yrs	€45.00k	geen gegevens
Francoise de Craecker	Independent Director	3.6yrs	€45.00k	geen gegevens

10.1yrs

Gemiddelde duur

56.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van SIGHT zijn ervaren en ervaren (gemiddelde ambtstermijn van 10.1 jaar).

GenSight Biologics Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Gensight Biologics S.A. Appoints William Monteith to Its Board of Directors

Gensight Biologics S.A. Announces CFO Changes

GenSight Biologics Announces Board Changes

GenSight Biologics S.A. Announces CEO Changes

Insufficient new directors

GenSight Biologics Appoints Philippe Motté as Senior Vice President, Regulatory and Quality

Recent updates

New major risk - Financial position

GenSight Biologics Announces Submission of LUMEVOQ Dossier to ANSM to Prepare for Restart of Early Access Program in France

First half 2024 earnings released: €0.071 loss per share (vs €0.26 loss in 1H 2023)

New major risk - Financial position

New major risk - Share price stability

GenSight Biologics S.A. Provides Business Update

Gensight Biologics S.A. Appoints William Monteith to Its Board of Directors

New major risk - Shareholder dilution

Full year 2023 earnings: EPS and revenues exceed analyst expectations

GenSight Biologics S.A. to Report Q3, 2024 Results on Oct 24, 2024

New major risk - Revenue and earnings growth

GenSight Biologics Announces Initial Results from New Meta-Analyses on Visual Outcomes with LUMEVOQ® Gene Therapy at NANOS 2024

GenSight Biologics Announces Update on Real-World Data from Early Access Programs of LUMEVOQ® Gene Therapy at NANOS 2024

New major risk - Shareholder dilution

GenSight Biologics S.A. has completed a Follow-on Equity Offering in the amount of €5 million.

Gensight Biologics S.A. Announces CFO Changes

New minor risk - Shareholder dilution

GenSight Biologics Announces Board Changes

GenSight Biologics S.A. Announces CEO Changes

Consensus revenue estimates decrease by 12%, EPS upgraded

Gensight Biologics S.A. Confirms Second Successful GMP Batch of Lumevoq

GenSight Biologics S.A. Announces Preliminary Assay Indicating Successful Manufacture of Second LUMEVOQ® GMP Batch

GenSight Biologics Provides Update on European Medicines Agency Scientific Advice for LUMEVOQ

GenSight Biologics Announces Successful Manufacture of LUMEVOQ GMP Batch

First half 2023 earnings released: €0.26 loss per share (vs €0.23 loss in 1H 2022)

Consensus revenue estimates decrease by 17%, EPS upgraded

Forecast to breakeven in 2025

No longer forecast to breakeven

Forecast to breakeven in 2025

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Forecast to breakeven in 2024

GenSight Biologics Announces 1 Year Safety Data and Efficacy Signals

Is There An Opportunity With GenSight Biologics S.A.'s (EPA:SIGHT) 30% Undervaluation?

GenSight Biologics Announces Publication of Indirect Comparison of LUMEVOQ Versus Natural History in ND4-LHON Patients in Peer-Reviewed Journal Ophthalmology and Therapy

GenSight Biologics Announces Publication of Results of LUMEVOQ® REFLECT Pivotal Clinical Trial in Peer-Reviewed Journals

Price target decreased to €10.67

Insufficient new directors

Is GenSight Biologics S.A. (EPA:SIGHT) Trading At A 39% Discount?

GenSight Biologics S.A Announces Successful Completion of LUMEVOQ Engineering Batch Validating Implemented Corrective Actions

GenSight Biologics Appoints Philippe Motté as Senior Vice President, Regulatory and Quality

Health Check: How Prudently Does GenSight Biologics (EPA:SIGHT) Use Debt?

Insufficient new directors

First half 2022 earnings released

Insufficient new directors

GenSight Biologics Announces Publication of a Study of the Impact of LHON Disease on the Lives of Patients and Relatives in Journal of Neuro-Ophthalmology

Price target decreased to €12.50

GenSight Biologics Grants Six-Month Extension in LUMEVOQ® European Regulatory Review

Full year 2021 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates increase by 19%

Price target decreased to €12.50

GenSight Biologics S.A. Provides Update on LUMEVOQ® Manufacturing Timeline

Gensight Biologics to Present Reflect Phase III Data with LUMEVOQ® At the NANOS 2022 Meeting

GenSight Biologics Appoints Sissel Rodahl as Senior Vice-President of Commercial Operations to Lead the Launch of Lumevoq® in Europe

GenSight Biologics Reports Clinically Meaningful Vision Improvement is Maintained 4 Years After One-time Treatment with LUMEVOQ® Gene Therapy

Forecast to breakeven in 2024

GenSight Biologics Announces Publication of Non-Human Primate Study Reporting Presence of LUMEVOQ® Vector DNA in Contralateral Eyes After Unilateral Injection

Price target decreased to €15.00

Price target decreased to €16.00

GenSight Biologics S.A. Announces Positive Data Safety Monitoring Board Review of Pioneer Phase I/II Clinical Trial of GS030 as Optogenetic Treatment for Retinitis Pigmentosa

GenSight Biologics Announces Publication Analyzing Visual Parameters of ND4-LHON Subjects Before LUMEVOQ® Treatment in Phase III Trials

GenSight Biologics Announces Publication of RESTORE Study Data Demonstrating Sustained Efficacy 3 Years After Unilateral Injection of LUMEVOQ

Rock star Growth Puts GenSight Biologics (EPA:SIGHT) In A Position To Use Debt

First half 2021 earnings released: €0.19 loss per share (vs €0.43 loss in 1H 2020)

GenSight Biologics S.A. Announces Approval of the LUMEVOQ® Cohort Temporary Authorization for Use in France

Gensight Biologics Reports Topline Results from Reflect Phase III Clinical Trial, Confirming Lumevoq® Efficacy Including Better Efficacy with Bilateral Treatment

GenSight Biologics S.A. (EPA:SIGHT) Shares Could Be 27% Below Their Intrinsic Value Estimate

GenSight Biologics Announces Publication of Indirect Comparison Showing Treatment Effect of LUMEVOQ versus Natural History in Frontiers in Neurology

GenSight Biologics S.A. (EPA:SIGHT): Is Breakeven Near?

GenSight Biologics S.A. Announces Publication of Results from the REALITY LHON Natural History Study in the Journal Eye